<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498914</url>
  </required_header>
  <id_info>
    <org_study_id>155-CL-009</org_study_id>
    <secondary_id>Eudra CT 2006-002584-70</secondary_id>
    <nct_id>NCT00498914</nct_id>
  </id_info>
  <brief_title>Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects</brief_title>
  <official_title>A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate,
      efficacy, safety and tolerability of YM155
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1 arm (Active), Phase 2 Study to evaluate response rate, efficacy, safety and tolerability of
      YM155
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility boundary at interim analysis not met
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>15 treatment cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, efficacy, pharmacokinetics, and tolerability</measure>
    <time_frame>15 treatment cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Lymphoma, Large-Cell, Diffuse</condition>
  <condition>Lymphoma, B-Cell Refractory</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM155</intervention_name>
    <description>Continuous IV infusion</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged 18 years or older

          -  Histologically confirmed primary DLBCL of any stage

          -  Refractory to the last treatment regimen

          -  Previously treated with the following treatment regimens:

          -  Anthracycline-based combination chemotherapy with rituximab

          -  Second-line combination chemotherapy

          -  Autologous BMT if the subject was eligible and did not refuse the procedure

          -  At least one measurable lesion defined as &gt; 1.5 cm in the longest diameter

          -  No known central nervous system involvement

          -  ECOG performance status &lt; 2

          -  Life expectancy &gt; 12 weeks

          -  If female, non-pregnant and non-lactating

          -  IRB-approved consent and HIPAA Authorization

        Exclusion Criteria:

          -  Transformed, composite or discordant lymphoma

          -  Therapy for lymphoma within 21 days prior to the first dose of YM155

          -  Within 4 weeks of the screening FDG-PET scan, receipt of the following:

          -  Radiation therapy

          -  Surgical procedures (except biopsies and central catheter / port placement)

          -  Active infection (bloodstream or deep tissue)

          -  Inadequate marrow, hepatic and/or renal function

          -  Serum creatinine &gt; 1.5 x ULN or calculated serum creatinine clearance &lt; 60 mL/min

          -  Absolute Neutrophil Count (ANC) &lt; 750/mm3

          -  Platelet &lt; 50,000/mm3

          -  Alanine Transaminase (ALT) and Aspartate Transaminase (AST) &gt; 2.5 x ULN; &gt; 5 x ULN if
             secondary to liver metastases

          -  Treated with &gt; 3 prior treatment regimens. The following should be considered:

          -  Planned maintenance therapy should be considered as part of the previous treatment
             regimen

          -  Any preparative treatment (salvage chemotherapy, high-dose chemotherapy, radiation
             therapy, etc.) should be included with the autologous BMT or PBSCT as one treatment

          -  Prior allogeneic BMT or PBSCT

          -  Previously treated with YM155

          -  Other investigational therapy or procedures within 28 days

          -  Known HIV, hepatitis B surface antigen, or hepatitis C antibody

          -  Other malignancy requiring treatment within 2 years

          -  Significant and/or uncontrolled cardiac, renal, hepatic, or other systemic disorders
             or significant psychological conditions that in the Investigator's judgment would
             jeopardize subject enrollment or compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <disposition_first_submitted>August 20, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 4, 2015</disposition_first_posted>
  <last_update_submitted>August 20, 2015</last_update_submitted>
  <last_update_submitted_qc>August 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma, Large-Cell, Diffuse</keyword>
  <keyword>Lymphoma, B-Cell</keyword>
  <keyword>YM155</keyword>
  <keyword>Treatment outcomes</keyword>
  <keyword>Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

